Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
  1. Home
  3. Hyaluronic Acid-modified Theranostic Niosomes For Targeted Fingolimod Delivery And Inhibition Of Triple-negative Breast Cancer Metastasis.
  1. Home
  3. Hyaluronic Acid-modified Theranostic Niosomes For Targeted Fingolimod Delivery And Inhibition Of Triple-negative Breast Cancer Metastasis.

Related Experiment Video

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K

Hyaluronic acid-modified theranostic niosomes for targeted Fingolimod delivery and inhibition of triple-negative

Zahra Hashemi1, Masoumeh Kaveh Zenjanab1, Mehdi Pourbakhsh1

  • 1Department of Medical Biotechnology, Faculty of Advanced Medical Sciences, Tabriz University of Medical Sciences, Tabriz, Iran.

Medical Oncology (Northwood, London, England)
|June 12, 2025

View abstract on PubMed

Summary
This summary is machine-generated.

Hyaluronic acid-coated niosomes encapsulating Fingolimod and quantum dots show enhanced targeted delivery and triple-negative breast cancer cell death. This novel nanoformulation effectively inhibits metastasis and improves therapeutic outcomes for aggressive breast cancer.

Keywords:
Drug deliveryFingolimodMetastasisNiosomeQuantum-dotTriple-negative breast cancer

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

338
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.5K

Related Experiment Videos

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

16.7K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

338
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.5K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Triple-negative breast cancer (TNBC) presents a significant therapeutic challenge due to its aggressive nature and high metastatic potential.
  • Current treatment strategies for TNBC often lack specificity, leading to systemic side effects and limited efficacy against metastatic disease.
  • Targeted drug delivery systems offer a promising approach to enhance therapeutic outcomes by concentrating anti-cancer agents at the tumor site.

Purpose of the Study:

  • To develop and characterize a novel nanoformulation, HNio@QDFTY720, for targeted therapy and metastasis inhibition of triple-negative breast cancer (TNBC).
  • To evaluate the efficacy of this nanoformulation in vitro, focusing on cellular uptake, cytotoxicity, apoptosis induction, and migration inhibition.
  • To investigate the potential of Fingolimod (FTY720) loaded niosomes, enhanced with hyaluronic acid and quantum dots, for improving TNBC treatment.

Main Methods:

  • Synthesis of hyaluronic acid (HA)-coated niosomes (NIOs) encapsulating Fingolimod (FTY720) and quantum dots (QDs) using the thin film hydration method (TFH).
  • Characterization of the nanoparticles (NPs) including size, polydispersity index (PDI), and zeta potential.
  • In vitro evaluation encompassing encapsulation efficiency, pH-sensitive drug release, cellular uptake studies (CD44+ MDA-MB-231 cells), MTT cytotoxicity assays, Annexin V-FITC/PI apoptosis analysis, and wound healing migration assays.
  • Bioinformatics analysis to correlate Fingolimod target genes with breast cancer patient survival.

Main Results:

  • The synthesized HNio@QDFTY720 NPs exhibited optimal characteristics with a size of 126.4 nm, PDI of 0.476, and zeta potential of -17.6 mV.
  • High encapsulation efficiency (98.5%) and pH-sensitive drug release were observed, with significantly higher release at acidic pH (5.8) compared to physiological pH (7.4).
  • Enhanced cellular uptake in CD44+ cells, superior cytotoxicity compared to free FTY720, significant induction of apoptosis and necrotic cell death, and complete inhibition of cell migration were demonstrated by the HNio@QDFTY720 formulation.
  • Bioinformatics analysis revealed a strong correlation between Fingolimod's target genes, cell motility, and breast cancer patient survival.

Conclusions:

  • The developed hyaluronic acid-coated niosomal formulation (HNio@QDFTY720) demonstrates significant potential for targeted delivery of Fingolimod in TNBC.
  • This nanoformulation effectively enhances the cytotoxic effects of FTY720, induces apoptosis, and inhibits metastasis in TNBC models.
  • HNio@QDFTY720 represents a promising therapeutic strategy for improving treatment outcomes in metastatic TNBC through targeted drug delivery and enhanced anti-cancer activity.